Global EditionASIA 中文双语Français
China Daily / 2022-04 / 27 / Page001

Vaccines against Omicron approved for clinical trials

By WANG XIAOYU | China Daily | Updated: 2022-04-27 00:00

Two homegrown Omicron-specific COVID-19 vaccine candidates developed by Sinopharm and Sinovac Biotech have been approved for clinical trials by China's top drug regulator, the two companies said on Tuesday.

If the trial proceeds successfully, the experimental vaccine from Sinopharm will likely be used as a third or fourth booster shot for fully vaccinated people age 18 and older, the company said.

China National Biotech Group, a subsidiary of Sinopharm, said in a statement released on its website that the vaccine was already cleared for clinical trials in Hong Kong on April 13.

Report cites rights progress in Tibet

Most Viewed

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US